Severe endothelial dysfunction in the aorta of a mouse model of Fabry disease; partial prevention by N-butyldeoxynojirimycin treatment.

Míreanna comhchosúla

• N-butyldeoxynojirimycin causes weight loss as a result of appetite suppression in lean and obese mice.
  de réir: Priestman, D, et al.
  Foilsithe / Cruthaithe: (2008)
• NSAIDs increase survival in the Sandhoff disease mouse: synergy with N-butyldeoxynojirimycin.
  de réir: Jeyakumar, M, et al.
  Foilsithe / Cruthaithe: (2004)
• N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo.
  de réir: Andersson, U, et al.
  Foilsithe / Cruthaithe: (2000)
• Long-term non-hormonal male contraception in mice using N-butyldeoxynojirimycin.
  de réir: Walden, C, et al.
  Foilsithe / Cruthaithe: (2006)
• The alpha-glucosidase inhibitor N-butyldeoxynojirimycin inhibits human immunodeficiency virus entry at the level of post-CD4 binding.
  de réir: Fischer, P, et al.
  Foilsithe / Cruthaithe: (1995)